Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
3 Unstoppable Stocks That Could Double in 5 Years
10:00am, Saturday, 29'th Oct 2022 The Motley Fool
The opportunities for these innovators are tremendous.
3 Unstoppable Stocks That Could Double in 5 Years
06:00am, Saturday, 29'th Oct 2022
The opportunities for these innovators are tremendous.
Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:02pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Fulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline
02:01pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
I Called This October Rally In August, Keep Your Seat Belts On
03:17am, Monday, 24'th Oct 2022 Seeking Alpha
After a barely discernible bottoming process, the rally has become obvious. Read more to see how I intend to take advantage of this rally.
2 Under-the-Radar Biotech Stocks to Buy in 2022
01:53pm, Wednesday, 19'th Oct 2022 The Motley Fool
These two drugmakers are growing in prominence.
2 Under-the-Radar Biotech Stocks to Buy in 2022
09:53am, Wednesday, 19'th Oct 2022
These two drugmakers are growing in prominence.
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71%
11:24am, Monday, 17'th Oct 2022 Benzinga
Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading.
Piper Sandler cut Patterson Companies, Inc. (NASDAQ: PDCO) pri
7 Analysts Have This to Say About Sarepta Therapeutics
01:05pm, Thursday, 13'th Oct 2022 Benzinga
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
4
Is Pfizer Stock Still Worth Buying After The Pandemic?
08:43am, Wednesday, 12'th Oct 2022 Investing.com
Big-Cap S&P Stocks Will Soon Provide Tech-Like Returns, I Explain
04:10am, Monday, 10'th Oct 2022 Seeking Alpha
Learn more about an opportunity to acquire well-known big-cap names in the S&P 500 that, at this point, could provide "tech-like" returns.
Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
12:30pm, Friday, 07'th Oct 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will share new data from across its genetic
The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
12:45pm, Thursday, 06'th Oct 2022 Zacks Investment Research
CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.
Stock Market Rallies Powerfully Off Lows; Lamb Weston, Sarepta, AMN In Focus | Stock Market Today
03:52pm, Wednesday, 05'th Oct 2022
But it's too early to declare a market bottom. Stock Market Today: October 5, 2022 Hosts: Ali Coram & Ken Shreve Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: h
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
01:18pm, Wednesday, 05'th Oct 2022 Zacks Investment Research
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.
